The Danish pharmaceutical giant heads into its quarterly report with a bruised share price and a pipeline narrative that has lost some of its shine. Two clinical disappointments in quick succession have forced investors to recalibrate expectations for a company long accustomed to delivering good news.
The CagriSema Disappointment
The more consequential blow landed on CagriSema, the candidate designed to succeed the blockbuster GLP-1 treatments Ozempic and Wegovy. A trial testing the 2.4-milligram dose produced a 23 percent weight loss after 84 weeks — a solid result by most measures, but one that fell short of the non-inferiority benchmark set by Eli Lilly’s Tirzepatid, which achieved 25.5 percent at its 15-milligram dose.
The market’s verdict was swift and severe. Shares tumbled 13 percent in Copenhagen, touching 263 Danish kroner — a level not seen since July 2021. The company has indicated that additional studies with higher doses are already in the pipeline, but the setback complicates the timeline for a successor product that was meant to extend the franchise well into the next decade.
A Second Setback in the Cardiovascular Arena
Just days earlier, on July 31, the ZEUS study had already delivered a dose of disappointment. The anti-inflammatory candidate Ziltivekimab succeeded in lowering biological markers such as free interleukin-6 and hsCRP, yet failed its primary endpoint: the hazard ratio for cardiovascular events came in at 0.99 versus placebo, implying virtually no added benefit over the control group. The stock shed up to 9 to 10 percent on the news.
Morningstar analyst Karen Andersen described the outcome as disappointing but noted that Ziltivekimab was expected to contribute only a modest share of company revenue by 2035. Novo Nordisk has maintained its 2026 operating profit guidance, though a non-cash impairment charge will hit the third-quarter results. Two further trials for the drug, HERMES and ARTEMIS, are not expected to report until the first half of 2027, leaving a cloud of uncertainty over the program for the foreseeable future.
A CEO Pivoting Toward Deal-Making
Chief executive Mike Doustdar — the first foreign-born leader at the helm of Novo Nordisk, approaching his one-year anniversary — is responding to the setbacks with a shift in strategy. He has signaled openness to acquisitions “of any size,” following the company’s $10 billion bid for Metsera, and has reportedly urged internal teams to embrace greater risk-taking. His blunt warning, according to reports from Copenhagen: “Arrogance kills.”
The strategic imperative is clear: reduce the company’s dependence on Ozempic and Wegovy, and build out a pipeline spanning cardiovascular disease, blood disorders, and NASH — preparations for the eventual patent expiration of semaglutide in the 2030s. The CEO has also expressed willingness to work with Washington, even as questions linger over how a new US tariff announcement aligns with existing trade agreements.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Legal Offensive Against Lilly
The competitive pressure has also pushed Novo Nordisk onto the offensive in the courtroom. On July 21, the company filed suit against Eli Lilly in the US District Court for the District of New Jersey, alleging misleading advertising for Lilly’s obesity treatments, including the recently launched Foundayo. The complaint centers on claims that Lilly’s marketing compares its highest dosages against lower doses of Novo products, relying on outdated clinical data.
The legal battle underscores just how intense the fight for share in the weight-loss market has become — a market projected to surpass $100 billion by the end of the decade. Novo Nordisk retains a strong position with the oral Wegovy pill, which launched on January 5, 2026, and had already surpassed three million prescriptions early in the year. But competitive pressure has intensified markedly since spring.
The Technical Picture and What’s at Stake
The share price tells its own story of investor unease. Over the past seven trading days, the stock has lost 8.05 percent, currently changing hands at €41.05. That leaves it roughly a quarter below its 52-week high of €54.86 from January — a gap of 25.16 percent that captures the magnitude of recent disappointments.
The technical backdrop is delicate. The current price sits just 1.21 percent above the 200-day moving average of €40.34, a level widely viewed as critical support. A decisive break below that mark would darken the chart picture considerably.
Institutional positioning presents a mixed picture. Heavyweights including Bank of America and Dimensional Fund Advisors trimmed their stakes in the first quarter, while smaller managers such as LFG Wealth Partners and Shariaportfolio established new positions. The analyst consensus remains “hold,” with price targets sitting comfortably above current levels.
For the second quarter, analysts expect earnings per share of $0.77 on revenue of roughly $10.89 billion. Several analysts anticipate that Wednesday’s report could bring an upward revision to full-year guidance, supported by robust Wegovy prescription trends. The question hanging over the earnings call is whether Novo Nordisk can rebuild investor confidence through its own operational performance — or whether the promised acquisition offensive will prove to be the decisive lever in restoring momentum.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from August 4 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 4.
Novo Nordisk: Buy or sell? Read more here...
